FibroBiologics (FBLG) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications.

• Utilizes a novel manufacturing process involving collection of excess tissue from surgical procedures to create allogeneic fibroblast cell banks.

• Lead product candidates include CYWC628, CYMS101, and CybroCell.

Financial performance and metrics

• Aggregate market value of outstanding common stock held by non-affiliates is $75.6 million, based on 30,367,274 shares at $2.49 per share as of December 6, 2024.

• Common stock is listed on the Nasdaq Global Market under the symbol "FBLG"; closing price was $1.61 per share on January 31, 2025.

Use of proceeds and capital allocation

• Net proceeds from securities sales are expected to be used for general corporate purposes, with potential initial investment in U.S. government obligations pending specific application.